FDA clears JenaValve Trilogy for severe aortic regurgitation

JenaValve’s Trilogy Transcatheter Heart Valve System has won FDA premarket approval for treating symptomatic, severe aortic regurgitation in patients at high or greater surgical risk, giving the U.S. market its first approved transcatheter option specifically for this disease. The company announced the decision in mid-March 2026 and positioned Trilogy as the first and only FDA-approved transcatheter device for symptomatic severe aortic regurgitation in the country. (jenavalve.com)

The approval closes a long development arc. JenaValve received FDA investigational device exemption approval in August 2021 to start the ALIGN-AR pivotal PMA trial in high-risk patients with severe symptomatic aortic regurgitation. That work built on earlier European momentum, where Trilogy received CE Mark in 2021 for both aortic regurgitation and aortic stenosis. In the meantime, Edwards Lifesciences moved to acquire JenaValve in 2024, highlighting how strategically important a dedicated transcatheter solution for aortic regurgitation had become. (jenavalve.com)

What made this indication difficult is that native aortic regurgitation often lacks the calcification that helps anchor conventional TAVR devices in aortic stenosis. ACC reporting notes that Trilogy was designed specifically for this problem, using a leaflet-clipping anchoring mechanism intended to reduce migration and paravalvular leak. That design is a major part of why the platform has drawn attention as a dedicated rather than adapted solution. (acc.org)

The clinical case for approval came from ALIGN-AR. ACC summaries describe the study as a prospective, multicenter, single-arm IDE trial conducted at U.S. centers in patients with symptomatic greater-than-moderate native aortic regurgitation who were considered high risk for surgery. Reported results included a 96.4% device success rate, only 1.5% of patients with more than mild residual regurgitation at 30 days, and low valve embolization rates. Investigators also reported improvements in left ventricular end-systolic and end-diastolic volume indices, suggesting favorable remodeling after treatment. (acc.org)

Expert reaction has been notably positive, though still framed around appropriate patient selection. In ACC materials tied to the 2025 presentation of updated ALIGN-AR data, lead investigator Dr. Raj Makkar said the study met prespecified safety and efficacy endpoints and showed strong valve hemodynamics with very low leakage across and around the valve. ACC commentary published after the approval also emphasized that current guidelines still favor surgical aortic valve replacement for operable patients, meaning Trilogy’s near-term role is most clearly in patients who are symptomatic and poor surgical candidates. (acc.org)

The approval also lands in a broader FDA environment that is becoming more receptive to specialized cardiovascular devices and software aimed at earlier detection or narrower clinical niches. One recent example is FDA 510(k) clearance for Anumana’s AI-enabled pulmonary hypertension algorithm, a software-as-a-medical-device that analyzes standard 12-lead ECGs for early PH patterns. According to PharmaShots’ summary of the company announcement, the tool was developed using more than 250,000 Mayo Clinic patient records, showed 73% sensitivity and 74.4% specificity in a 21,066-patient multicenter U.S. study, and in a real-world analysis identified more than 85% of pulmonary arterial hypertension cases and 78% of chronic thromboembolic pulmonary hypertension cases using ECGs captured between symptom onset and diagnosis. The software is also designed to integrate with EHR and ECG management systems while operating within the health system environment without transferring patient data. (PharmaShots)

Why it matters: For veterinary professionals, this is primarily a regulation and device-innovation story, but it also has broader relevance. It shows how FDA can create a path for highly specialized cardiovascular devices when a sponsor targets a clearly defined unmet need, builds a focused pivotal dataset, and demonstrates that a disease-specific design solves a known anatomical limitation. For clinicians in comparative and translational medicine, Trilogy’s approval is a reminder that structural heart innovation is moving beyond broad valve categories toward indication-specific engineering and tighter risk stratification. The Anumana clearance points in a similar direction on the diagnostics side: regulators are also clearing workflow-friendly cardiovascular software that uses familiar tests such as routine ECGs to surface disease earlier rather than waiting for advanced presentation. (jenavalve.com; PharmaShots)

It also matters operationally. JenaValve’s U.S. materials say the procedure should be performed by physicians experienced in TAVR and trained on the Trilogy system, with emergency cardiac surgery available if needed. That means uptake is likely to concentrate first in established structural heart programs rather than diffuse immediately across all centers. Coverage and coding will also influence adoption, especially because CMS has already listed a study evaluating Trilogy versus surgical valve replacement in aortic regurgitation, signaling that evidence development around this category is still evolving. The same operational theme appears in newer cardiovascular software clearances: products that fit existing infrastructure, such as ECG-based algorithms that plug into EHR and ECG management systems without exporting patient data, may face fewer implementation barriers than tools that require entirely new workflows. (jenavalve.com; PharmaShots)

What to watch: Watch for FDA publication of the PMA documentation and any post-approval study requirements, broader reimbursement clarity, and whether future evidence supports expansion beyond today’s high-risk symptomatic population into earlier or lower-risk use. More broadly, keep an eye on whether FDA continues pairing approvals for highly specialized interventional devices with clearances for AI-enabled cardiovascular screening tools that can identify disease earlier inside routine clinical workflows. (fda.gov; PharmaShots)